Nonsmall cell lung carcinoma: diagnostic difficulties in small biopsies and cytological specimens

被引：65

作者：

Bubendorf, Lukas ^{[1
]}

Lantuejoul, Sylvie ^{[2
,3
]}

de langen, Adrianus J. ^{[4
]}

Thunnissen, Erik ^{[5
]}

机构：

[1] Univ Basel, Inst Pathol, Basel, Switzerland

[2] UNICANCER, Ctr Leon Berard, Dept Biopathol, Lyon, France

[3] Grenoble Alpes Univ, CNRS 5309, INSERM, Inst Adv Biosci,U1209, Grenoble, France

[4] Vrije Univ Amsterdam Med Ctr, Dept Resp Dis, Amsterdam, Netherlands

[5] Vrije Univ Amsterdam Med Ctr, Dept Pathol, De Boelelaan 1117, NL-1081 HV Amsterdam, Netherlands

来源：

EUROPEAN RESPIRATORY REVIEW | 2017年 / 26卷 / 144期

关键词：

IN-SITU HYBRIDIZATION; MOLECULAR TESTING GUIDELINE; OF-AMERICAN-PATHOLOGISTS; ALK GENE REARRANGEMENT; ROS1; REARRANGEMENTS; PHASE-III; ONCOGENE MUTATIONS; PD-L1; EXPRESSION; CANCER PATIENTS; OPEN-LABEL;

D O I：

10.1183/16000617.0007-2017

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

The pathological and molecular classification of lung cancer has become substantially more complex over the past decade. For diagnostic purposes on small samples, additional stains are frequently required to distinguish between squamous cell carcinoma and adenocarcinoma. Subsequently, for advanced nonsquamous cell nonsmall cell lung carcinoma (NSCLC) patients, predictive analyses on epidermal growth factor receptor, anaplastic lymphoma kinase and ROS1 are required. In NSCLCs negative for these biomarkers, programmed death ligand-1 immunohistochemistry is performed. Small samples (biopsy and cytology) require " tissue" management, which is best achieved by the interaction of all physicians involved.

引用

页数：15

共 124 条

[1] ALK Rearrangement in a Large Series of Consecutive Non-Small Cell Lung Cancers
Ali, Greta
Proietti, Agnese
Pelliccioni, Serena
Niccoli, Cristina
Lupi, Cristiana
Sensi, Elisa
Giannini, Riccardo
Borrelli, Nicla
Menghi, Maura
Chella, Antonio
Ribechini, Alessandro
Cappuzzo, Federico
Melfi, Franca
Lucchi, Marco
Mussi, Alfredo
Fontanini, Gabriella
[J]. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2014, 138 (11) : 1449 - 1458
[2] Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)
Barlesi, Fabrice
Mazieres, Julien
Merlio, Jean-Philippe
Debieuvre, Didier
Mosser, Jean
Lena, Herve
Ouafik, L'Houcine
Besse, Benjamin
Rouquette, Isabelle
Westeel, Virginie
Escande, Fabienne
Monnet, Isabelle
Lemoine, Antoinette
Veillon, Remi
Blons, Helene
Audigier-Valette, Clarisse
Bringuier, Pierre-Paul
Lamy, Regine
Beau-Faller, Michele
Pujol, Jean-Louis
Sabourin, Jean-Christophe
Penault-Llorca, Frederique
Denis, Marc G.
Lantuejoul, Sylvie
Morin, Franck
Quan Tran
Missy, Pascale
Langlais, Alexandra
Milleron, Bernard
Cadranel, Jacques
Soria, Jean-Charles
Zalcman, Gerard
[J]. LANCET, 2016, 387 (10026) : 1415 - 1426
[3] The use of stained cytologic direct smears for ALK gene rearrangement analysis of lung adenocarcinoma
Betz, Bryan L.
Dixon, Catherine A.
Weigelin, Helmut C.
Knoepp, Stewart M.
Roh, Michael H.
[J]. CANCER CYTOPATHOLOGY, 2013, 121 (09) : 489 - 499
[4] EGFR and KRAS Mutations in Lung Carcinoma Molecular Testing by Using Cytology Specimens
Billah, Shahreen
Stewart, John
Staerkel, Gregg
Chen, Su
Gong, Yun
Guo, Ming
[J]. CANCER CYTOPATHOLOGY, 2011, 119 (02) : 111 - 117
[5] p40 (ΔNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma
Bishop, Justin A.
Teruya-Feldstein, Julie
Westra, William H.
Pelosi, Giuseppe
Travis, William D.
Rekhtman, Natasha
[J]. MODERN PATHOLOGY, 2012, 25 (03) : 405 - 415
[6] Prevalence and Clinical Outcomes for Patients With ALK-Positive Resected Stage I to III Adenocarcinoma: Results From the European Thoracic Oncology Platform Lungscape Project
Blackhall, Fiona H.
Peters, Solange
Bubendorf, Lukas
Dafni, Urania
Kerr, Keith M.
Hager, Henrik
Soltermann, Alex
O'Byrne, Kenneth J.
Dooms, Christoph
Sejda, Aleksandra
Hernandez-Losa, Javier
Marchetti, Antonio
Savic, Spasenija
Tan, Qiang
Thunnissen, Erik
Speel, Ernst-Jan M.
Cheney, Richard
Nonaka, Daisuke
de Jong, Jeroen
Martorell, Miguel
Letovanec, Igor
Rosell, Rafael
Stahel, Rolf A.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (25) : 2780 - +
[7] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
Borghaei, H.
Paz-Ares, L.
Horn, L.
Spigel, D. R.
Steins, M.
Ready, N. E.
Chow, L. Q.
Vokes, E. E.
Felip, E.
Holgado, E.
Barlesi, F.
Kohlhaeufl, M.
Arrieta, O.
Burgio, M. A.
Fayette, J.
Lena, H.
Poddubskaya, E.
Gerber, D. E.
Gettinger, S. N.
Rudin, C. M.
Rizvi, N.
Crino, L.
Blumenschein, G. R.
Antonia, S. J.
Dorange, C.
Harbison, C. T.
Finckenstein, F. Graf
Brahmer, J. R.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) : 1627 - 1639
[8] ROS1 Immunohistochemistry Among Major Genotypes of Non-Small-Cell Lung Cancer
Boyle, Theresa A.
Masago, Katsuhiro
Ellison, Kim E.
Yatabe, Yasushi
Hirsch, Fred R.
[J]. CLINICAL LUNG CANCER, 2015, 16 (02) : 106 - 111
[9] ALK and ROS1 Rearrangements Tested by Fluorescence In Situ Hybridization in Cytological Smears From Advanced Non-Small Cell Lung Cancer Patients
Bozzetti, Cecilia
Nizzoli, Rita
Tiseo, Marcello
Squadrilli, Anna
Lagrasta, Costanza
Buti, Sebastiano
Gasparro, Donatello
Zanoni, Daniele
Majori, Maria
De Filippo, Massimo
Mazzoni, Francesca
Maddau, Cristina
Naldi, Nadia
Sammarelli, Gabriella
Frati, Caterina
Pinto, Carmine
Ardizzoni, Andrea
[J]. DIAGNOSTIC CYTOPATHOLOGY, 2015, 43 (11) : 941 - 946
[10] ALK translocation detection in non-small cell lung cancer cytological samples obtained by TBNA or EBUS-TBNA
Bravaccini, S.
Tumedei, M. M.
Ulivi, P.
Zoli, W.
Calistri, D.
Candoli, P.
Amadori, D.
Puccetti, M.
[J]. CYTOPATHOLOGY, 2016, 27 (02) : 103 - 107

← 1 2 3 4 5 6 7 8 9 10 →